NLS Pharmaceutics AG logo

NLS Pharmaceutics AGNASDAQ: NLSP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Switzerland

IPO:

29 January 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$15.90 M
-74%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector
-103%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:52:47 GMT
$4.17+$0.47(+12.65%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

NLSP Latest News

Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
investorplace.com29 July 2024 Sentiment: POSITIVE

NLS Pharmaceutics (NASDAQ: NLSP ) stock is on the rise Monday after the clinical-stage biopharmaceutical company announced a merger agreement with Kadimastem. This agreement will see Kadimastem acquired by a wholly-owned subsidiary of NLS Pharmaceutics.

Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
investorplace.com20 June 2024 Sentiment: NEGATIVE

NLS Pharmaceutics (NASDAQ: NLSP ) stock is down on Thursday but that's only after the clinical-stage biopharmaceutical company's shares underwent a massive rally on Tuesday. Shares of NLSP stock closed out Tuesday, the prior day of trading due to the Juneteenth holiday on Wednesday, up 82.1%.

Why Is NLS Pharmaceutics (NLSP) Stock Down 24% Today?
InvestorPlace04 December 2023 Sentiment: NEGATIVE

NLS Pharmaceutics (NASDAQ: NLSP ) stock is taking a beating on Monday as the company's shares come down from a rally on Friday. The news that sent shares of NLSP stock higher on Friday concerned an exclusive option to license in-license Aexon Labs' Dual Orexin Receptor Agonists platform.

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies
Market Watch03 July 2023 Sentiment: POSITIVE

Shares of NLS Pharmaceutics Ltd. NLSP, +19.57% gained 12% premarket on Monday after the Swiss clinical-stage biopharma company said it would proceed with phase 3 clinical studies of Mazindol ER, a treatment for narcolepsy.

NLS Pharmaceutics Company Update and Webcast Today Postponed
Accesswire30 June 2023 Sentiment: NEUTRAL

NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update.

CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Accesswire19 June 2023 Sentiment: NEGATIVE

Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20, 2023, at 10:30 AM ET.

NLS Pharmaceutics Announces Company Update Webcast
Accesswire19 June 2023 Sentiment: POSITIVE

Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, including: Feedback from the SLEEP 2023 APSS Conference Initiation of the Phase 3 program AMAZE for Mazindol ER Pipeline Goals for 2023/2024 Key Financials Funding Strategy Update Corporate Development Webcast Information The event will be held June 30, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website here or at the SummitCast event page here.

NLS Pharmaceutics Announces Company Update Webcast
Accesswire15 June 2023 Sentiment: POSITIVE

Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / June 15, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, including: Feedback from the SLEEP 2023 APSS Conference Initiation of the Phase 3 program AWARE for Mazindol ER Pipeline Goals for 2023/2024 Key Financials Funding Strategy Update Corporate Development Webcast Information The event will be held June 30, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website here.

What type of business is NLS Pharmaceutics AG?

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

What sector is NLS Pharmaceutics AG in?

NLS Pharmaceutics AG is in the Healthcare sector

What industry is NLS Pharmaceutics AG in?

NLS Pharmaceutics AG is in the Biotechnology industry

What country is NLS Pharmaceutics AG from?

NLS Pharmaceutics AG is headquartered in Switzerland

When did NLS Pharmaceutics AG go public?

NLS Pharmaceutics AG initial public offering (IPO) was on 29 January 2021

What is NLS Pharmaceutics AG website?

https://nlspharma.com

Is NLS Pharmaceutics AG in the S&P 500?

No, NLS Pharmaceutics AG is not included in the S&P 500 index

Is NLS Pharmaceutics AG in the NASDAQ 100?

No, NLS Pharmaceutics AG is not included in the NASDAQ 100 index

Is NLS Pharmaceutics AG in the Dow Jones?

No, NLS Pharmaceutics AG is not included in the Dow Jones index

When was NLS Pharmaceutics AG the previous earnings report?

No data

When does NLS Pharmaceutics AG earnings report?

Next earnings report date is not announced yet